12/5
08:09 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
12/5
08:08 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its "outperform" rating reaffirmed by analysts at Wedbush.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) had its "outperform" rating reaffirmed by analysts at Wedbush.
12/4
07:00 am
dnli
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
Medium
Report
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
11/17
12:08 pm
dnli
Denali Therapeutics (NASDAQ:DNLI) was given a new $37.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) was given a new $37.00 price target on by analysts at Stifel Nicolaus.
11/6
07:03 pm
dnli
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights [Yahoo! Finance]
Low
Report
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights [Yahoo! Finance]
11/6
04:11 pm
dnli
Denali Therapeutics Announces Board and Executive Leadership Updates [Yahoo! Finance]
Low
Report
Denali Therapeutics Announces Board and Executive Leadership Updates [Yahoo! Finance]
11/6
04:01 pm
dnli
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Medium
Report
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
11/6
04:00 pm
dnli
Denali Therapeutics Announces Board and Executive Leadership Updates
Medium
Report
Denali Therapeutics Announces Board and Executive Leadership Updates
11/4
10:28 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $26.00. They now have an "overweight" rating on the stock.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $26.00. They now have an "overweight" rating on the stock.
10/13
04:21 pm
dnli
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) [Yahoo! Finance]
Low
Report
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) [Yahoo! Finance]
10/13
04:01 pm
dnli
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
Low
Report
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
9/10
08:05 pm
dnli
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? [Yahoo! Finance]
9/8
09:58 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.